Data asset expected to drive improvements in patient outcomes and care quality.
Fresenius Medical Care announced the completion of Phase I of the company's first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company's long-term AI aspirations. The database intends to advance patient care quality and outcomes by making kidney disease care more personalized and precise.
"Dialysis care generates a large amount of data that can be used for secondary purposes, but multinational datasets are scarce due to the fundamental need for adherence to varying complex data protection regulations around the world, as well as the challenges in harmonization of data from different clinical systems," said Len Usvyat, PhD, head of clinical advanced analytics, Fresenius Medical Care. "This important data tool increases the speed and robustness of the company's analytical capabilities and provides greater consistency in generating data-driven clinical insights. The knowledge gained from these efforts have the potential to improve not just the practice of medicine, but more importantly the quality of life for people with kidney disease."
Reference: Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset. PR Newswire. October 26, 2023. Accessed October 26, 2023. https://www.prnewswire.com/news-releases/fresenius-medical-care-achieves-key-ai-milestone-with-first-phase-completion-of-largest-global-dialysis-clinical-dataset-301968900.html
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.